Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.

    CAMBRIDGE, Mass., Feb. 12 /CNW/ -- Mersana, a cancer therapeutics
company, announced today that Timothy B. Lowinger, Ph.D., has joined the
company as Chief Scientific Officer.
    "We are thrilled that Tim is now a part of the Mersana team," said Julie
A. Olson, President and CEO at Mersana. "His extensive leadership in oncology
research and his experience with polymer-based drug systems are an ideal match
for Mersana. In addition to the important impact he will have on our newest
programs, his contributions toward advancing our lead product, XMT-1001, and
our second product, XMT-1107, will be significant."
    Dr. Lowinger has over fifteen years of experience in the pharmaceutical
industry and brings a wealth of international experience to his new role in
leading our Research team. From 1993 to 2007, Dr. Lowinger held a number of
positions at Bayer Pharmaceuticals in the US, Germany, and Japan, where he
contributed to the discovery of more than 15 pre-clinical and clinical
candidates in a variety of indications. Most notably, he led the team that
discovered and advanced Nexavar(R) (sorafenib), an anti-cancer agent that is
approved for indications including renal and hepatocellular cancer, with Phase
III studies underway in non-small-cell lung and other cancers. Later, as the
VP and Department Head of Chemistry Research in West Haven, he managed a
department of scientists in the disciplines of medicinal, analytical,
computational, combinatorial and synthetic chemistry, focused on the discovery
and clinical proof-of-concept of new therapeutics for the treatment of cancer,
diabetes and obesity. He has most recently been VP of Chemistry and
Pharmaceutical Sciences at Angiotech Pharmaceuticals where he managed a
multidisciplinary team of scientists focused on developing polymer-based
pharmaceutical products for local administration as well as medical devices
incorporating pharmaceutical agents. Dr. Lowinger has a BSc in Chemistry and a
Ph.D. in Organic Chemistry from the University of British Columbia in
Vancouver, Canada.
    About Mersana Therapeutics, Inc.
    Mersana, a privately held, venture backed company, utilizes its
proprietary nanotechnology platform to transform existing and experimental
anti-cancer agents into new, patentable drugs with superior pharmaceutical
properties. The key component of Mersana's platform is Fleximer(R), a novel,
biodegradable and bio-inert polymer that can be chemically linked to small
molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer-
camptothecin conjugate which is currently in Phase 1 clinical trials, and
several preclinical oncology compounds. Mersana's investors include Fidelity
Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and
PureTech Ventures.
    Fleximer(R) is a trademark of Mersana Therapeutics, Inc.

For further information:

For further information: Pete Leone, Chief Operating Officer of Mersana 
Therapeutics, Inc., +1-617-498-0020; or Media, Kathryn Morris of KMorrisPR, 

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890